A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

November 28, 2017

Study Completion Date

November 28, 2017

Conditions

Alopecia Areata

Interventions

DRUG

Tralokinumab

All groups will receive study drug every two weeks for 24 weeks.

DRUG

Placebo

Matching placebo given every two weeks for 24 weeks

Trial Locations (1)

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors

lead

Emma Guttman

OTHER

NCT02684097 - A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata | Biotech Hunter | Biotech Hunter